Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. Jul-Aug 2008;70(4):445-9.
doi: 10.4103/0250-474X.44591.

A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability of BCM-95CG (Biocurcumax), A Novel Bioenhanced Preparation of Curcumin

Affiliations
Free PMC article

A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability of BCM-95CG (Biocurcumax), A Novel Bioenhanced Preparation of Curcumin

B Antony et al. Indian J Pharm Sci. .
Free PMC article

Abstract

Curcumin, the bioactive component of turmeric, Curcuma longa has an exceptionally wide spectrum of activities including antioxidant, anti-inflammatory and anti-cancer properties, and is currently under different phases of clinical trials for various types of soft tissue cancers. However, although in vitro and animal studies have shown anticancer activities of curcumin for virtually all types of human cancers, its poor bioavailability in the human body has severely limited its application to these diseases. Methods to increase its oral bioavailability are a subject of intense current research. Reconstituting curcumin with the non-curcuminoid components of turmeric has been found to increase the bioavailability substantially. In the present clinical study to determine the bioavailability of curcuminoids, a patented formulation, BCM-95((R))CG was tested on human volunteer group. Normal curcumin was used in the control group. Curcumin content in blood was estimated at periodical intervals. After a washout period of two weeks the control group and drug group were crossed over BCM-95((R))CG and curcumin, respectively. It was also compared with a combination of curcumin-lecithin-piperine which was earlier shown to provide enhanced bioavailability. The results of the study indicate that the relative bioavailability of BCM-95((R))CG (Biocurcumax) was about 6.93-fold compared to normal curcumin and about 6.3-fold compared to curcumin-lecithin-piperine formula. BCM-95((R))CG thus, has potential for widespread application for various chronic diseases.

Keywords: Curcuma longa; Curcumin; anticancer; antioxidant; bioavailability; biocurcumax.

Figures

Fig. 1
Fig. 1
HPLC profile of curcumin from blood plasma. Blood plasma was extracted with ethyl acetate successively; all the washings were pooled and dried. This was dissolved in methanol and 20μl of this solution was injected into the HPLC column. The retention time obtained was 3 min which is the same for standard curcumin.
Fig. 2
Fig. 2
Mean plasma concentration of curcumin from BCM-95®CG (Biocurcumax™) and curcumin control. This figure shows the bioavailability of curcumin from blood plasma of the subjects taking BCM-95® CG (Biocurcumax™) and curcumin at a single dose of 2000 mg. Blood was drawn before consuming the capsules (0 h) and 1, 2, 3, 4 ½ 6 and 8 h. (formula image) shows the concentration of curcumin in the BCM-95® CG (Biocurcumax™) group whereas (formula image) that of curcumin group.
Fig. 3
Fig. 3
Mean plasma concentration of curcumin from BCM-95®CG (Biocurcumax™) and curcumin-lecithin-piperine groups. This figure shows the bioavailability of curcumin from blood plasma of the subjects taken BCM-95® CG (Biocurcumax™) and curcumin-lecithin-piperine complex at a single dose of 2000 mg. The blood was drawn before consuming the capsules (0 h) and 1, 2, 3, 4 ½,, 6 and 8 h (formula image) shows the concentration of curcumin in the BCM 95® CG (BiocurcumaxTM) group where as (formula image) that of curcumin + lecithin + piperine complex group.

Similar articles

See all similar articles

Cited by 48 articles

See all "Cited by" articles

References

    1. Maheshwari RK, Sing AK, Gaddipati J, Srimal RC. Multiple biological effects of curcumin: A short review. Life Sci. 2006;78:2081–7. - PubMed
    1. Bengmark S. Curcumin, a toxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: A shield against acute and chronic diseases. J Parenter Enter Nutr. 2006;30:45–51. - PubMed
    1. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006;71:1397–421. - PubMed
    1. Sharma RA, Gescher AJ, Steward WP. Curcumin: The story so far. Eur J Cancer. 2005;41:1955–68. - PubMed
    1. Duvoix A, Blasius R, Delhelle S, Schnekenburger M, Morceau F, Henry E, et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett. 2005;223:181–90. - PubMed

LinkOut - more resources

Feedback